Mark A. Tomai PhD

Mark Tomai, PhD currently works in Business Development at 3M Drug Delivery Systems. He is responsible for licensing/development agreements involving its transdermal product offerings including 3M’s microneedle platform and also licensing its toll-like receptor (TLR) 7 and 8 agonists for a variety of uses.

Dr. Tomai spent 16 years working in 3M Pharmaceuticals in Drug Discovery and Preclinical Development. He is an expert on TLR7 and TLR8 agonists and an author on over 80 publications and inventor on 12 issued patents in this area.